Drug Trial Radar · NCT05868876
A Phase Ia/Ib Open Label,Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
70
Actual
Start
Jul 26, 2023
Primary completion
Mar 4, 2026
Study completion Mar 4, 2026
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- May 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase Ia/Ib open label,clinical study evaluating the safety, tolerability and preliminary efficacy of AK127 in combination with AK104 in patients with advanced malignant tumors
Conditions
- Advanced Malignant Tumors
Interventions
AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusionDrug
AK127 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages.AK104 is administered intravenously according to the frequency and dosage 10mg/kg Q3W.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events(AE);Time frame: Up to approximately 2 years
- Incidence of serious adverse events(SAE);Time frame: Up to approximately 2 years
- Incidence of immune-related adverse events(irAE);Time frame: Up to approximately 2 years
- The incidence of suspected unexpected serious adverse reactions(SUSAR);Time frame: Up to approximately 2 years
- Incidence of dose-limiting toxicity(DLT);Time frame: Up to approximately 2 years
- Number of participants with clinically significant changes in laboratory assessment data as assessed by CTCAE v5.0.Time frame: Up to approximately 2 years
- AE that leads to the termination or suspension of treatment.Time frame: Up to approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.